http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005097122-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97c3dde920d2824019a9ddbe5c119c27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4180fc57a693864e2ce2dbfd64a9278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f16fdd3fd1900f2ada38f46e065e7320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00becb8919000b24992c52c87aa1daae http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76c9ec2fbd49ab4c4ff8fedc2ec9380f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2005-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b156fd9a6dd9d70b793114fa64ae8621 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d9c7daa9c11938bb0fc31796c2230e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_366717e270db4c9e8856fa8780d75558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccb5920e3dd6d5e2f872a3590d256b15 |
| publicationDate | 2006-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005097122-A3 |
| titleOfInvention | Method of treating schizophrenia and/or glucoregulatory abnormalities |
| abstract | The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula (I) wherein m is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, hydroxy, nitro or amino; each R1 is independently hydrogen, C1-C6alkyl, C1-C6alkenyl, C1-C6alkanoyl, halogen, cyano, -C(O) C1-C6alkyl, -C1-C6alkyleneCN, -C1-C6alkyleneNR’R” wherein R’ and R” are each independently hydrogen or C1-C6alkyl, -C1-C6alkyleneOC(O)C1-C6alkyl, or -CH(OH)R4 wherein R4 is hydrogen or C1-C6alkyl; R2 is hydrogen, C1-C6alkyl optionally substituted with halogen, hydroxy or benzyloxy, C1-C6alkenyl, C1-C6alkynyl, -CO2C1-C6alkyl, or -R5-NR’R” wherein R5 is C1-C6alkylene, C1-C6alkenylene or C1-C6alkynylene and R’ and R” are each independently hydrogen, C1-C6alkyl or alternatively the group -NR’R” as a whole is 1-pyrrolidinyl; and R3 is hydrogen, nitro, amino, halogen, C1-C6alkoxy, hydroxy or C1-C6alkyl or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2004-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.